Zobrazeno 1 - 10
of 126
pro vyhledávání: '"Shigeru Sakano"'
Autor:
Teruo Inamoto, Hideyasu Matsuyama, Naokazu Ibuki, Kazumasa Komura, Kiyohide Fujimoto, Hiroaki Shiina, Shigeru Sakano, Kazuhiro Nagao, Makito Miyake, Hiroaki Yasumoto, Haruhito Azuma
Publikováno v:
Therapeutic Advances in Urology, Vol 10 (2018)
Background: Chronological age is an important factor in determining the treatment options and clinical response of patients with upper tract urothelial carcinoma (UTUC). Much evidence suggests that chronological age alone is an inadequate indicator t
Externí odkaz:
https://doaj.org/article/0f42445d2cb54858933eec5420fc6b6b
Autor:
Miwa Sasaki, Shigeru Sakano, Naoko Okayama, Jumpei Akao, Tomohiko Hara, Yoshihisa Kawai, Chietaka Ohmi, Yuji Hinoda, Katsusuke Naito
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 10, Iss 3, Pp 255-265 (2008)
Upper urinary tract transitional cell carcinoma (UUT-TCC) is quite an uncommon disease, and its prognosis differs among individuals irrespective of tumor stage. DNA repair gene polymorphisms are reported to result in the modulation of the repair capa
Externí odkaz:
https://doaj.org/article/d066c1fd29bc42d9b1adaa677105383a
Autor:
Tomohiko Hara, Satoru Yoshihiro, Hideaki Ito, Kazuhiro Nagao, Chietaka Ohmi, Shigeru Sakano, Hideyasu Matsuyama, Katsusuke Naito
Publikováno v:
Clinical Medicine Insights: Oncology, Vol 1 (2007)
Background Metronomic chemotherapy is aimed at lessening the adverse effects of treatment while rendering cancer cells cytostatic. The oral 5-fluorouracil prodrug “5′-DFUR” has been shown to inhibit angiogenesis and is regarded as a good candid
Externí odkaz:
https://doaj.org/article/4eb6537034bc42a098fd0e065c6baebb
Autor:
Yuki Nakayama1 abcd6191986@gmail.com, Shigeru Sakano1, Yota Shinohara1, Jun Nishijima1, Yoshimasa Ban2, Yukihiro Hidaka2, Masashi Fukuda2, Koji Shiraishi2
Publikováno v:
Asian Journal of Endoscopic Surgery. Oct2023, Vol. 16 Issue 4, p679-686. 8p.
Autor:
Ikko, Tomisaki, Mirii, Harada, Shigeru, Sakano, Michikazu, Terado, Ryoichi, Hamasuna, Shuji, Harada, Hiroomi, Matsumoto, Soichiro, Akasaka, Yujiro, Nagata, Akinori, Minato, Ken-Ichi, Harada, Naohiro, Fujimoto
Publikováno v:
Anticancer Research. 43:269-274
We aimed to clarify the association between body mass index (BMI) and clinical outcomes of pembrolizumab treatment for advanced urothelial cancer (UC).We retrospectively reviewed the records of patients with advanced UC who received pembrolizumab aft
Autor:
Ikko Tomisaki, Mirii Harada, Shigeru Sakano, Michikazu Terado, Ryoichi Hamasuna, Shuji Harada, Hiroomi Matsumoto, Soichiro Akasaka, Yujiro Nagata, Akinori Minato, Ken‐ichi Harada, Naohiro Fujimoto
Publikováno v:
International Journal of Urology.
Autor:
Naokazu Ibuki, Hideyasu Matsuyama, Kiyohide Fujimoto, Makito Miyake, Haruhito Azuma, Teruo Inamoto, Hiroaki Mastumoto, Yoshihiro Tatsumi, Hiroaki Yasumoto, Kazumasa Komura, Shigeru Sakano, Hiroaki Shiina, Kazuhiro Nagao
Publikováno v:
Curr Urol
INTRODUCTION AND OBJECTIVES: The predictive impact of primary tumor location for patients with upper-tract urothelial carcinoma (UTUC) in the presence of concomitant urothelial bladder cancer, along with urothelial recurrence after the curative treat
Publikováno v:
Nihon Toseki Igakkai Zasshi. 52:47-53
Autor:
Hideyasu Matsuyama, Naokazu Ibuki, Shigeru Sakano, Hiroaki Shiina, Kazumasa Komura, Kazuhiro Nagao, Kiyohide Fujimoto, Hiroaki Yasumoto, Makito Miyake, Haruhito Azuma, Teruo Inamoto
Publikováno v:
Therapeutic Advances in Urology, Vol 10 (2018)
Therapeutic Advances in Urology
Therapeutic Advances in Urology
Background: Chronological age is an important factor in determining the treatment options and clinical response of patients with upper tract urothelial carcinoma (UTUC). Much evidence suggests that chronological age alone is an inadequate indicator t
Severe hypoglycaemia under abemaciclib administration in a patient with breast cancer: A case report
Autor:
Minekazu Yamaguchi, Shingo Yamagata, Shigeru Sakano, Miyako Horie, Kazutaka Kurokohchi, Tsunetaka Kijima, Kazunari Ishitobi, Satoshi Honda, Tatsuo Horie
Publikováno v:
Molecular and Clinical Oncology
The current study reports the case of an 80-year-old woman who experienced severe hypoglycaemia after abemaciclib administration, with a recovery time of ~46 h. Abemaciclib is a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor that is used to treat